Tumor burden is predictive of survival in patients with non-small-cell lung cancer and with activating epidermal growth factor receptor mutations who receive gefitinib

Clinical Lung Cancer

Volumn 14, Issue 4, 2013, Pages 383-389

  Park, Jin Hyun ^a   Kim, Tae Min ^a,b   Keam, Bhumsuk ^a,b   Jeon, Yoon Kyung ^a   Lee, Se Hoon ^a,b   Kim, Dong Wan ^a,b   Chung, Doo Hyun ^a   Kim, Young Tae ^a   Kim, Young Whan ^a   Heo, Dae Seog ^a,b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

Clinical predictors; EGFR mutation; Gefitinib; Non small cell lung cancer; Tumor burden

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB;

ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; DRUG RESPONSE; FEMALE; GENE MUTATION; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PLEURA METASTASIS; PROGRESSION FREE SURVIVAL;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE; TUMOR BURDEN;

EID: 84878785768     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2012.10.007     Document Type: Article

References (29)

1. J.G. Paez, P.A. Jänne, J.C. Lee EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
2. R. Sordella, D.W. Bell, D.A. Haber Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways Science 305 2004 1163 1167
3. T.J. Lynch, D.W. Bell, R. Sordella Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
4. T.S. Mok, Y.L. Wu, S. Thongprasert Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
5. M. Maemondo, A. Inoue, K. Kobayashi Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2010 2380 2388
6. F.R. Hirsch, M. Varella-Garcia, P.A. Bunn Jr Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer J Clin Oncol 24 2006 5034 5042
7. N. Thatcher, A. Chang, P. Parikh Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa survival evaluation in lung cancer) Lancet 366 2005 1527 1537
8. S.W. Han, T.Y. Kim, K.H. Lee Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients Lung Cancer 54 2006 201 207
9. R. Rosell, T. Moran, C. Queralt Screening for epidermal growth factor receptor mutations in lung cancer N Engl J Med 361 2009 958 967
10. T. Mitsudomi, S. Morita, Y. Yatabe Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol 11 2010 121 128
11. S. Kobayashi, T.J. Boggon, T. Dayaram EGFR mutation and resistance of non-small-cell lung cancer to gefitinib N Engl J Med 352 2005 786 792
12. J.A. Engelman, K. Zejnullahu, T. Mitsudomi MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling Science 316 2007 1039 1043
13. S. Yuan, S.L. Yu, H.Y. Chen Clustered genomic alterations in chromosome 7p dictate outcomes and targeted treatment responses of lung adenocarcinoma with EGFR-activating mutations J Clin Oncol 29 2011 3435 3442
14. Q. Zhou, X.C. Zhang, Z.H. Chen Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer J Clin Oncol 29 2011 3316 3321
15. R. Rosell, M.A. Molina, C. Costa Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations Clin Cancer Res 17 2011 1160 1168
16. Y.T. Kim, T.Y. Kim, D.S. Lee Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung Lung Cancer 59 2008 111 118
17. L.H. Schwartz, J. Bogaerts, R. Ford Evaluation of lymph nodes with RECIST; 1.1 Eur J Cancer 45 2009 261 267
18. E.A. Eisenhauer, P. Therasse, J. Bogaerts New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
19. E.L. Kaplan, P. Meier Nonparametric estimation from incomplete observation J Am Stat Assoc 53 1958 457 481
20. R.A. Joss, K. Bürki, P. Dalquen Combination chemotherapy with mitomycin, vindesine, and cisplatin for non-small cell lung cancer Association of antitumor activity with initial tumor burden and treatment center Cancer 65 1990 2426 2434
21. Y. Oh, S. Taylor, B.N. Bekele Number of metastatic sites is a strong predictor of survival in patients with nonsmall cell lung cancer with or without brain metastases Cancer 115 2009 2930 2938
22. J.H. Goldie, A.J. Coldman The genetic origin of drug resistance in neoplasms: implications for systemic therapy Cancer Res 44 1984 3643 3653
23. B.M. Alexander, M. Othus, H.B. Caglar Tumor volume is a prognostic factor in non-small-cell lung cancer treated with chemoradiotherapy Int J Radiat Oncol Biol Phys 79 2011 1381 1387
24. S. Liao, B.C. Penney, K. Wroblewski Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer Eur J Nucl Med Mol Imaging 39 2012 27 38
25. J. Foo, F. Michor Evolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategies PLoS Comput Biol 5 2009 e1000557
26. J. Chmielecki, J. Foo, G.R. Oxnard Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling Sci Transl Med 3 2011 90ra59
27. K.Y. Su, H.Y. Chen, K.C. Li Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer J Clin Oncol 30 2012 433 440
28. D. Jackman, W. Pao, G.J. Riely Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer J Clin Oncol 28 2009 357 360
29. S. Morita, I. Okamoto, K. Kobayashi Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations Clin Cancer Res 15 2009 4493 4498